(Q37681577)

22 August 2017

1 reference

title

Roflumilast in chronic obstructive pulmonary disease: evidence from large trials (English)

1 reference

chronic obstructive pulmonary disease

22 August 2017

main subject

1 reference

Mario Cazzola

1

1 reference

22 August 2017

Stefano Picciolo

series ordinal

2

1 reference

22 August 2017

Maria G Matera

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

441-449

1 reference

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Glucocorticoid resistance in inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Are phosphodiesterase 4 inhibitors just more theophylline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

The efficacy and safety of cilomilast in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Inhaled corticosteroids in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

PDE4 inhibitors: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Novel signal transduction modulators for the treatment of airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903555201

10.1517/14656560903555201

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference